Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176449 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Bupropion SR and Placebo for Smoking Cessation
A Phase 4 study of Tobacco Use Disorder, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT00176449 is a Phase 4 study of Tobacco Use Disorder that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 52 participants, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00176449, a Phase 4 study of Tobacco Use Disorder, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine whether the adjunctive use of bupropion SR in the context of a psychoeducational program modified for people with schizophrenia might improve the likelihood of successful abstinence in this population. If bupropion SR is effective for reducing cigarette smoking, then it will be important to determine if decreased nicotine intake is associated with a worsening of psychotic, anxiety or depressive symptoms. In addition, it would be important to determine the effect that a reduction in nicotine stimulation would have on patient's cognitive functioning, as nicotinic receptors have been shown to regulate attention and memory function, and it is hypothesized that these functions are normalized by acute nicotine administration in people with schizophrenia
Conditions Studied
Interventions
- DRUG Placebo Oral Tablet
- DRUG Bupropion SR
Study Locations (1)
Maryland
- Maryland Psychiatric REsearch Center - Catonsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2001-04 |
| Est. Completion | 2005-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176449
The ClinicalTrials.gov registry entry for NCT00176449 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (78% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT00176449 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00176449 about?
NCT00176449 is a clinical study titled "A Comparison of Bupropion SR and Placebo for Smoking Cessation". The purpose of this study is to examine whether the adjunctive use of bupropion SR in the context of a psychoeducational program modified for people with schizophrenia might improve the likelihood of successful abstinence in this population. If bupropion SR is effective for reducing cigarette smokin...
What is the current status of trial NCT00176449?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2001-04. Estimated completion is 2005-12.
What conditions does trial NCT00176449 study?
This clinical trial studies the following conditions: Tobacco Use Disorder.
What interventions are being tested in trial NCT00176449?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Bupropion SR (DRUG).
Who is sponsoring clinical trial NCT00176449?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00176449 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Beta-Adrenergic Modulation of Drug Cue Reactivity
RECRUITING · Phase 4
-
E-cigarette Cessation in Adults Who Co-use Cannabis
RECRUITING · Phase 4
-
Varenicline and Combined NRT for Smoking Cessation
ACTIVE NOT RECRUITING · Phase 4
-
Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence
COMPLETED · Phase 4
-
Varenicline Effects In Schizophrenic Smokers
COMPLETED · Phase 4
-
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.